National cancer incidence is estimated using the incidence/mortality ratio in countries with local incidence data: is this estimation correct?
Our results support the validity of I/M approaches for national estimations, except for thyroid cancer. The longitudinal version of this approach has, furthermore, the advantage of providing smoothed estimations and trend analyses, including useful birth-cohort indicators, and should thus be preferred.
NO, but not prostacyclin, is a major mediator of PSD.